Why are there significant differences in published narrowband ultraviolet B dosimetry recommendations? The need for national standardization of phototherapy treatment - 28/07/11
, Tina Bhutani, MD b, Patricia B. McClelland, RN b, John Y.M. Koo, MD b
Reprint requests: Madelaine M. Haddican, MS, UCSF Psoriasis Treatment Center, 515 Spruce Street, San Francisco, CA, 94118.Abstract |
Narrowband ultraviolet B phototherapy is an important treatment option for psoriasis and other skin diseases. When narrowband ultraviolet B phototherapy is initiated, one method involves determining the minimal erythema dose for each patient with the starting dose at 50% to 70% of the minimal erythema dose. An alternative method involves using the recommended narrowband ultraviolet B exposure dose based on a patient's Fitzpatrick skin type. When the recommended narrowband ultraviolet B exposure doses of separate publications are compared, alarming differences are found. These discrepancies not only create confusion but also suggest the risk of phototoxicity, or its opposite, namely the risk of suboptimal dosimetry. For these reasons, this article discusses possible explanations for the wide variation in dosimetry recommendations. To remedy the current situation, the authors advocate a national standard for the practice of phototherapy treatment with the guidelines of the United Kingdom as a possible model for emulation.
Le texte complet de cet article est disponible en PDF.Key words : dosimetry, Fitzpatrick skin type, guidelines, irradiance, narrowband UVB, phototherapy, phototoxicity
Abbreviations used : BB-UVB, MED, NB-UVB, PUVA, UCSF, UVB
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Koo has received research support and /or lecture honoraria from the following companies: Abbott Labs, Amgen, Astellas, Galderma, Genentech, Photomedix, Ranbaxy, Stiefel, Teikoku, and Warner Chilcott. Authors Haddican, Bhutani, and McClelland have no conflicts to declare. |
Vol 65 - N° 2
P. 411-414 - août 2011 Retour au numéro
Article précédent
- Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma
- Astrid Blom, Marie Beylot-Barry, Michel D'Incan, Liliane Laroche
- POEMS syndrome: Are current diagnostic criteria too exclusive?
- Yann Charli-Joseph, Mónica Fernández-Sánchez, Marcela Saeb-Lima, Rocío Orozco-Topete
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?